The good oncogene: When bad genes identify good outcome in cancer

Medical Hypotheses

Volumn 76, Issue 2, 2011, Pages 259-263

  Lee, Jonathan M ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ELONGATION FACTOR 1; ELONGATION FACTOR 1A2; FIBROBLAST GROWTH FACTOR 18; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE CA; PROTEIN KINASE LCK; PROTEIN TYROSINE KINASE; RECEPTOR TYROSINE KINASE KIT; STAT1 PROTEIN; TRANSFORMING GROWTH FACTOR BETA3; UNCLASSIFIED DRUG; WNT1 PROTEIN;

ARTICLE; CANCER CELL; CANCER DIAGNOSIS; CANCER SURVIVAL; GENE CONTROL; HUMAN; HUMAN CELL; NEOPLASM; ONCOGENE; OUTCOME ASSESSMENT; PROGNOSIS; PROTEIN EXPRESSION; SENESCENCE; SURVIVAL TIME; TUMOR GROWTH; TUMOR PROMOTION;

ANIMALS; CELL AGING; DISEASE PROGRESSION; EUKARYOTIC INITIATION FACTOR-1; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MODELS, BIOLOGICAL; MODELS, GENETIC; NEOPLASM METASTASIS; NEOPLASMS; ONCOGENES; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 78651085351     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2010.10.015     Document Type: Article

References (73)

1. Segal E., et al. From signatures to models: understanding cancer using microarrays. Nat Genet 2005, 37(Suppl):S38-S45.
2. Nielsen D.L., Andersson M., Kamby C. HER2-targeted therapy in breast cancer, monoclonal antibodies and tyrosine kinase inhibitors. Cancer Treat Rev 2009, 35(2):121-136.
3. van de Vijver M.J., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347(25):1999-2009.
4. Chen H.Y., et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007, 356(1):11-20.
5. Hershey J.W. Translational control in mammalian cells. Annu Rev Biochem 1991, 60:717-755.
6. Jeganathan S., et al. Eukaryotic elongation factor 1A2 cooperates with phosphatidylinositol-4 kinase III beta to stimulate production of filopodia through increased phosphatidylinositol-4, 5 bisphosphate generation. Mol Cell Biol 2008, 28(14):4549-4561.
7. Jeganathan S., Lee J.M. Binding of elongation factor eEF1A2 to phosphatidylinositol 4-kinase beta stimulates lipid kinase activity and phosphatidylinositol 4-phosphate generation. J Biol Chem 2007, 282(1):372-380.
8. Balla A., Balla T. Phosphatidylinositol 4-kinases: old enzymes with emerging functions. Trends Cell Biol 2006, 16(7):351-361.
9. Anand N., et al. Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer. Nat Genet 2002, 31(3):301-305.
10. Li R., et al. Identification of putative oncogenes in lung adenocarcinoma by a comprehensive functional genomic approach. Oncogene 2006, 25(18):2628-2635.
11. Tomlinson V.A., et al. Expression of eEF1A2 is associated with clear cell histology in ovarian carcinomas: overexpression of the gene is not dependent on modifications at the EEF1A2 locus. Br J Cancer 2007, 96(10):1613-1620.
12. Pinke D.E., et al. The prognostic significance of elongation factor eEF1A2 in ovarian cancer. Gynecol Oncol 2008, 108(3):561-568.
13. Chambers D.M., Peters J., Abbott C.M. The lethal mutation of the mouse wasted (wst) is a deletion that abolishes expression of a tissue-specific isoform of translation elongation factor 1alpha, encoded by the Eef1a2 gene. Proc Natl Acad Sci USA 1998, 95(8):4463-4468.
14. Potter M., Bernstein A., Lee J.M. The wst gene regulates multiple forms of thymocyte apoptosis. Cell Immunol 1998, 188(2):111-117.
15. Kulkarni G., et al. Expression of protein elongation factor eEF1A2 predicts favorable outcome in breast cancer. Breast Cancer Res Treat 2007, 102(1):31-41.
16. Fruman D.A., Meyers R.E., Cantley L.C. Phosphoinositide kinases. Annu Rev Biochem 1998, 67:481-507.
17. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002, 2(7):489-501.
18. Maruyama N., et al. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women. Clin Cancer Res 2007, 13(2 Pt 1):408-414.
19. Li S.Y., et al. PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res Treat 2006, 96(1):91-95.
20. Kalinsky K., et al. PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 2009, 15(16):5049-5059.
21. Campbell I.G., et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004, 64(21):7678-7681.
22. Buttitta F., et al. PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma. J Pathol 2006, 208(3):350-355.
23. Barbareschi M., et al. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res 2007, 13(20):6064-6069.
24. Gymnopoulos M., Elsliger M.A., Vogt P.K. Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci USA 2007, 104(13):5569-5574.
25. Bader A.G., Kang S., Vogt P.K. Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci USA 2006, 103(5):1475-1479.
26. Isakoff S.J., et al. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 2005, 65(23):10992-11000.
27. Samuels Y., et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer cell 2005, 7(6):561-573.
28. Zhao J.J., et al. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci USA 2005, 102(51):18443-18448.
29. Yarden Y., et al. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. Embo J 1987, 6(11):3341-3351.
30. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000, 103(2):211-225.
31. Besmer P. The kit ligand encoded at the murine Steel locus: a pleiotropic growth and differentiation factor. Curr Opin Cell Biol 1991, 3(6):939-946.
32. Roskoski R. Structure and regulation of Kit protein-tyrosine kinase-the stem cell factor receptor. Biochem Biophys Res Commun 2005, 338(3):1307-1315.
33. Ray P., Krishnamoorthy N., Ray A. Emerging functions of c-kit and its ligand stem cell factor in dendritic cells: regulators of T cell differentiation. Cell Cycle 2008, 7(18):2826-2832.
34. Garrido M.C., Bastian B.C. KIT as a therapeutic target in melanoma. J Invest Dermatol 2010, 130(1):20-27.
35. Hutt K.J., McLaughlin E.A., Holland M.K. Kit ligand and c-Kit have diverse roles during mammalian oogenesis and folliculogenesis. Mol Hum Reprod 2006, 12(2):61-69.
36. Sharma S., et al. Stem cell c-KIT and HOXB4 genes: critical roles and mechanisms in self-renewal, proliferation, and differentiation. Stem Cells Dev 2006, 15(6):755-778.
37. Caruana G., et al. Transformation of NIH3T3 fibroblasts by the c-Kit receptor tyrosine kinase: effect of receptor density and ligand-requirement. Oncogene 1998, 16(2):179-190.
38. Hines S.J., et al. Coexpression of the c-kit and stem cell factor genes in breast carcinomas. Cell Growth Differ 1995, 6(6):769-779.
39. Lev S., Yarden Y., Givol D. Receptor functions and ligand-dependent transforming potential of a chimeric kit proto-oncogene. Mol Cell Biol 1990, 10(11):6064-6068.
40. Khalifeh I., et al. The impact of c-kit and ki-67 expression on patients prognosis in advanced ovarian serous carcinoma. Int J Gynecol Pathol 2005, 24(3):228-234.
41. Tonary A.M., et al. Lack of expression of c-KIT in ovarian cancers is associated with poor prognosis. Int J Cancer 2000, 89(3):242-250.
42. Tsutsui S., et al. A loss of c-kit expression is associated with an advanced stage and poor prognosis in breast cancer. Br J Cancer 2006, 94(12):1874-1878.
43. Thornton S., et al. Not just for housekeeping: protein initiation and elongation factors in cell growth and tumorigenesis. J Mol Med 2003, 81(9):536-548.
44. Roskoski R. Signaling by Kit protein-tyrosine kinase-the stem cell factor receptor. Biochem Biophys Res Commun 2005, 337(1):1-13.
45. Gotzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev 2009;4:CD001877.
46. Samayawardhena L.A., Kapur R., Craig A.W. Involvement of Fyn kinase in Kit and integrin-mediated Rac activation, cytoskeletal reorganization, and chemotaxis of mast cells. Blood 2007, 109(9):3679-3686.
47. Amiri A., et al. EEF1A2 activates Akt and stimulates Akt-dependent actin remodeling, invasion and migration. Oncogene 2007, 26(21):3027-3040.
48. Kolsch V., Charest P.G., Firtel R.A. The regulation of cell motility and chemotaxis by phospholipid signaling. J Cell Sci 2008, 121(Pt 5):551-559.
49. Suresh S. Biomechanics and biophysics of cancer cells. Acta Biomater 2007, 3(4):413-438.
50. Tai P., et al. Short- and long-term cause-specific survival of patients with inflammatory breast cancer. BMC Cancer 2005, 5:137.
51. Cannistra S.A. Cancer of the ovary. N Engl J Med 2004, 351(24):2519-2529.
52. Dawson S.J., Provenzano E., Caldas C. Triple negative breast cancers: clinical and prognostic implications. Eur J Cancer 2009, 45(Suppl. 1):27-40.
53. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100(1):57-70.
54. Lazebnik Y. What are the hallmarks of cancer?. Nat Rev Cancer 2010, 10(4):232-233.
55. Weinberg R.A. Mechanisms of malignant progression. Carcinogenesis 2008, 29(6):1092-1095.
56. Klein C.A. Parallel progression of primary tumours and metastases. Nat Rev Cancer 2009, 9(4):302-312.
57. Serrano M., et al. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997, 88(5):593-602.
58. Mallette F.A., Ferbeyre G. The DNA damage signaling pathway connects oncogenic stress to cellular senescence. Cell Cycle 2007, 6(15):1831-1836.
59. Sarkisian C.J., et al. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol 2007, 9(5):493-505.
60. Al-Hajj M., et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003, 100(7):3983-3988.
61. Dalerba P., Cho R.W., Clarke M.F. Cancer stem cells: models and concepts. Annu Rev Med 2007, 58:267-284.
62. Huh W.K., et al. Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a gynecologic oncology group phase II Trial in women with recurrent or persistent carcinosarcomas of the uterus. Gynecol Oncol 2010, 117(2):248-254.
63. Courtney K.D., Corcoran R.B., Engelman J.A. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010, 28(6):1075-1083.
64. Wiedlocha A., Sorensen V. Signaling, internalization, and intracellular activity of fibroblast growth factor. Curr Top Microbiol Immunol 2004, 286:45-79.
65. Zakrzewska M., Marcinkowska E., Wiedlocha A. FGF-1: from biology through engineering to potential medical applications. Crit Rev Clin Lab Sci 2008, 45(1):91-135.
66. Weintraub S.J., Manson S.R., Deverman B.E. Resistance to antineoplastic therapy. The oncogenic tyrosine kinase-Bcl-x(L) axis. Cancer Cell 2004, 5(1):3-4.
67. Alarcon B., van Santen H.M. Two receptors, two kinases, and T cell lineage determination. Sci Signal 2010, 3(114):pe11.
68. Wymann M.P., Marone R. Phosphoinositide 3-kinase in disease: timing, location, and scaffolding. Curr Opin Cell Biol 2005, 17(2):141-149.
69. Kim H.S., Lee M.S. STAT1 as a key modulator of cell death. Cell Signal 2007, 19(3):454-465.
70. Khodarev N.N., et al. Signal transducer and activator of transcription 1 regulates both cytotoxic and prosurvival functions in tumor cells. Cancer Res 2007, 67(19):9214-9220.
71. Massague J. TGFbeta in Cancer. Cell 2008, 134(2):215-230.
72. Takahashi-Yanaga F., Kahn M. Targeting Wnt signaling: can we safely eradicate cancer stem cells?. Clin Cancer Res 2010, 16(12):3153-3162.
73. Dravid G., et al. Defining the role of Wnt/beta-catenin signaling in the survival, proliferation, and self-renewal of human embryonic stem cells. Stem cells 2005, 23(10):1489-1501.